Union Bancaire Privee UBP SA Acquires Shares of 3,000 DexCom, Inc. (NASDAQ:DXCM)

Union Bancaire Privee UBP SA bought a new position in DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 3,000 shares of the medical device company’s stock, valued at approximately $225,000.

Other institutional investors also recently modified their holdings of the company. Blue Whale Capital LLP grew its holdings in DexCom by 91.9% in the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after purchasing an additional 113,000 shares during the period. Brooktree Capital Management bought a new stake in shares of DexCom in the 3rd quarter worth approximately $683,000. National Pension Service grew its stake in shares of DexCom by 4.1% in the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock worth $63,671,000 after buying an additional 37,363 shares during the last quarter. Intact Investment Management Inc. bought a new position in DexCom during the 3rd quarter valued at approximately $650,000. Finally, Motley Fool Asset Management LLC raised its stake in DexCom by 168.7% during the third quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company’s stock valued at $17,993,000 after buying an additional 171,150 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Performance

NASDAQ:DXCM opened at $90.75 on Tuesday. The stock has a 50-day simple moving average of $83.50 and a two-hundred day simple moving average of $76.11. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The firm has a market capitalization of $35.46 billion, a PE ratio of 63.46, a P/E/G ratio of 2.30 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on DXCM shares. Canaccord Genuity Group raised their price target on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Citigroup upped their target price on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and raised their price target for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Finally, Wells Fargo & Company upped their price objective on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $99.06.

Insider Activity

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,083 shares of company stock worth $3,309,794 in the last three months. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.